Completed PHASE3 INTERVENTIONAL 2-arm NCT01516970

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)

HIV Postexposure Prophylaxis With Darunavir/r (PEPDar)

Sponsor: Janssen-Cilag G.m.b.H

Conditions Human Immunodeficiency Virus (HIV)

Interventions Darunavir/Ritonavir (DRV/r) Efavirenz Lopinavir in fixed combination with Ritonavir NRTIs Zidovudine

Updated 8 times since 2017 Last updated: Jun 21, 2017 Started: Nov 25, 2011 Primary completion: Aug 1, 2013 Completion: Sep 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01516970, this PHASE3 trial focuses on Human Immunodeficiency Virus (HIV) and remains completed. Sponsored by Janssen-Cilag G.m.b.H, it has been updated 8 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Aug 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag G.m.b.H

Data source: Janssen-Cilag G.m.b.H

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bonn, Germany , Cologne, Germany , Dortmund, Germany , Dresden, Germany , Düsseldorf, Germany , Erlangen, Germany , Frankfurt, Germany , Freiburg im Breisgau, Germany , Hamburg, Germany and 7 more locations